Pantherna Therapeutics is a biotechnology company developing mRNA-based medicines, with an emphasis on diseases involving the vascular endothelium and respiratory system. The company designs and formulates therapeutic mRNA using lipid nanoparticle (LNP) delivery technologies, advancing programs from discovery through preclinical development. Pantherna Therapeutics is based in Germany.
The company’s activities bridge biopharma R&D and chemical process expertise, including nucleic acid synthesis, lipid selection, and nanoparticle formulation. It collaborates with manufacturing partners to scale mRNA and LNP processes toward clinical readiness, focusing on reproducible, cost-effective production and rigorous quality standards.
